Verve Therapeutics Inc (VERV) 옵션

VERV 10Q due Monday 2/24

VERV new 52 week low

VERV new 52 week low

VERV 10Q due AUGUST5

VERV new 52 week low

VERV new 52 week low

VERV more new lows up ahead

VERV new 52 week low

VERV new 52 week low

VERV new 52 week low

VERV new 52 week low

VERV new 52 lo

uh oh

VERV over $10

Looking for an entry now

Could see another nice move here is the 50 day holds into close.

VERV morning rally

https://cathiesark.com/

VERV IS A GREAT $$$$$ OPPORTUNITY.

Verve Therapeutics started at outperform with $48 stock price target at BMO Capital

Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.